Form 4: Iovance Biotherapeutics COO Reports Stock Transaction
Insider Transaction (Form 4)
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on September 8, 2026.
Summary
- Option exercise/conversion: acquired 7,813 Common Stock on September 8, 2026; holds 146,050 after (Direct).
- Tax/exercise-price withholding: disposed of 3,976 Common Stock at $8.70 ($34,591) on September 8, 2026; holds 142,074 after (Direct).
- Option exercise/conversion: disposed of 7,813 Restricted Stock Units on September 8, 2026; holds 46,878 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Igor Bilinsky — Officer (Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-08 | Option exercise/conversion | Common Stock | 7,813 | — | — | 146,050 |
| 2026-09-08 | Tax/exercise-price withholding | Common Stock | 3,976 | $9 | $34.6K | 142,074 |
| 2026-09-08 | Option exercise/conversion | Restricted Stock Units | 7,813 | — | — | 46,878 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-08 | Option exercise/conversion (7,813 shares) |
| 2026-09-08 | Tax/exercise-price withholding (3,976 shares) |
| 2026-09-08 | Option exercise/conversion (7,813 shares) |
Keywords
insider transaction, Form 4, IOVA, IOVANCE BIOTHERAPEUTICS, INC., neutral, Igor Bilinsky
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.